AnnexVIR-2
| Reference number | |
| Coordinator | Annexin Pharmaceuticals AB |
| Funding from Vinnova | SEK 1 800 000 |
| Project duration | June 2016 - August 2019 |
| Status | Completed |
Important results from the project
The purpose of AnnexVIR-2 is to perform initial in-vitro studies to investigate whether Annexin A5 has the potential to reduce mortality in persons affected by hemorrhagic fevers (e.g. Ebola). The project has also included formulation work and funding related activities. The goal of the project is to obtain sufficient data to enable decisions about more extensive studies on Annexin A5 and hemorrhagic fevers.
Expected long term effects
The obtained results have formed the basis for the Company´s future strategy. The company continues its development work with Annexin A5 as possible pharmaceutical product for hemorrhagic fevers (specifically at Ebola).
Approach and implementation
The project has been carried out by Annexin Pharmaceuticals in collaboration with subcontractors who are specialists in manufacturing of biological pharmaceutical products and the execution of safety-classified in-vitro studies. The execution of the project has taken considerably longer time than planned due to an unexpected need for re-formulation. In-vitro studies have been postponed due to unexpected situations in the safety-classified laboratory.